EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes

Rafael Cantón iD, María García-Castillo, Marta Hernández-García iD, Miquel Àngel Sastre-Femenía, Carla López-Causapé iD, Patricia Ruiz-Garbajosa, Lucía García Labrador, Christopher Longshaw, Antonio Oliver

Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)

DOI: 10.1093/jac/dkag164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 26.05.2026. Verfasst von Rafael Cantón und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Hauptthemen laut MEDLINE: Cephalosporins, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd., Osaka, Japan, Shionogi, CIBERINFEC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The PERSEUS study was a retrospective analysis of cefiderocol use under the compassionate use and early access programmes in Spain for the treatment of MDR Gram-negative infections. We present the microbiological evaluation of 57 isolates collected from this study, along with their correlation to clinical outcomes.

Methods

Cefiderocol susceptibility testing was performed using standard broth microdilution (BMD) in iron-depleted media, commercial BMD panels (UMIC®, ComASP®), gradient MIC strips, and disk diffusion. Results were interpreted according to EUCAST 2024 criteria. WGS was used to characterize β-lactamase genes and mutations in genes implicated in cefiderocol resistance. Patients’ clinical charts were reviewed.

Results

Most isolates were identified as Pseudomonas aeruginosa (72%). Cefiderocol demonstrated an overall susceptibility rate of 86%, outperforming most comparators except colistin. Commercial BMD devices demonstrated high concordance with the reference method, supporting their potential value for routine use. Molecular analysis revealed a high prevalence of class B metallo-β-lactamases, as well as mutations in iron transport genes, among resistant isolates. Notably, clinical cure was achieved even in patients infected with cefiderocol-resistant isolates treated with cefiderocol monotherapy, suggesting that some putative resistance mechanisms affect the MIC, without necessarily leading to clinical failure.

Conclusions

Positive clinical outcomes in patients infected by cefiderocol-resistant isolates by EUCAST breakpoints highlight the need for standardized susceptibility testing, as well as deeper genotype-phenotype correlation studies. Cefiderocol remains a promising option for treating MDR Gram-negative infections, especially those caused by P. aeruginosa. Its adoption in clinical practice should be supported by validated testing methods and ongoing surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalosporinsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialGram-Negative Bacterial InfectionsGram-Negative BacteriaCefiderocolHumansMicrobial Sensitivity Testsbeta-LactamasesRetrospective StudiesSpainTreatment OutcomePseudomonas aeruginosaCompassionate Use Trials

Substanzen

CefiderocolCephalosporinsAnti-Bacterial Agentsbeta-Lactamases

Autor:innen und Institutionen

  • Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Medical Affairs, Shionogi S.L.U., Madrid, Spain.
  • Medical Affairs, Shionogi B.V., London, UK.

ORCID-Profile: Rafael Cantón, Marta Hernández-García, Carla López-Causapé

Förderung

  • Shionogi & Co., Ltd., Osaka, Japan
  • Shionogi
  • CIBERINFEC
  • Instituto de Salud Carlos III, Spain

Zitieren

APA

Cantón, R., García-Castillo, M., Hernández-García, M., Sastre-Femenía, M. À., López-Causapé, C., Ruiz-Garbajosa, P., García Labrador, L., Longshaw, C., & Oliver, A. (2026). Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag164

Vancouver

Cantón R, García-Castillo M, Hernández-García M, Sastre-Femenía MÀ, López-Causapé C, Ruiz-Garbajosa P, et al. Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag164

BibTeX
@article{Cantn2026,
  author = {Cantón, Rafael and García-Castillo, María and Hernández-García, Marta and Sastre-Femenía, Miquel Àngel and López-Causapé, Carla and Ruiz-Garbajosa, Patricia and García Labrador, Lucía and Longshaw, Christopher and Oliver, Antonio},
  title = {Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {6},
  doi = {10.1093/jac/dkag164}
}
Kostenlos starten →